K
rüppel-like factor 4 (KLF4) is a master transcription factor regulating the anti-inflammatory phenotype of both vascular endothelial cells (ECs) and monocytes/macrophages. Physiological stimuli (eg, atheroprotective flow) and cardiovascular drugs (eg, statins) exert their beneficial effects in part through the induction of KLF4 in ECs and monocytes.
1,2 Although a higher level of KLF4 in ECs regulates the expression of genes such as endothelial nitric oxide synthase (eNOS), 3, 4 induction of KLF4 in the macrophage favors the transition from the proinflammatory M1 to antiinflammatory M2 phenotype. 5 At the disease level, the atheroprotective role of KLF4 in ECs and monocytes/ macrophages is demonstrated by increased atherosclerosis in apolipoprotein E (ApoE)-null mice with either EC-specific or myeloid-specific KLF4 ablation. 6, 7 Cholesterol 25-hydroxylase (Ch25h) modulates cholesterol and lipid metabolism by converting cholesterol to . 8 Recent studies demonstrate that 25-HC, the product of Ch25h, increases the antiviral effect and innate immunity in the host. [9] [10] [11] Liu et al 12 indicated that interferon enhances Ch25h-25-HC which suppressed viral growth through blocking virus fusion to the host cell membrane. Reboldi et al 13 found that Ch25h-25-HC suppresses nucleotide-binding oligomerization domain, leucine-rich repeat and pryin domain containing 3 (NLRP3)-dependent interleukin (IL)-1β production in macrophages and inhibits septic shock in mouse models. SREBP2 (sterol regulatory elementbinding protein 2) and liver X receptor (LXR) are 2 transcription factors that regulate cholesterol biosynthesis and metabolism reciprocally. 14 SREBP2 is a key mediator of genes involved in cholesterol biosynthesis (eg, 3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] reductase) and uptake (eg, low-density lipoprotein ([LDL] receptor) and induces NLRP3 inflammasome in ECs. 15 Belonging to the nuclear receptor superfamily, LXR transactivates genes such as ATP-binding cassette (ABC) transporters, ABCA1 and ABCG1, to promote reverse cholesterol transport. 16 Ligand-dependent LXR activation in ECs is associated with reduced oxidative stress and increased eNOS activity. 17 Furthermore, administration of a synthetic LXR ligand to ApoE -/-or LDL receptor -/-mice decreased atherosclerosis. 18 By contrast, bone marrow transplantation from LXRα/β -/-mice to ApoE -/-or LDL receptor -/-recipients resulted in a marked increase of atherosclerotic lesion size. 19 It is interesting to note that 25-HC inhibits the transcriptional activity of SREBP2 20 while serving as an agonistic ligand for LXR. 21 The initiation, development, and advancement of atherosclerosis involve multiple inflammatory events in the endothelium, circulatory monocytes, and resident macrophages in the arterial wall. The sum of the proinflammatory responses counteracting the anti-inflammatory responses in these cell types determines the progression and severity of atherosclerosis. Given the dual role of 25-HC in inhibiting SREBP2 and activating LXR, we postulate that physiological stimuli and cardiovascular therapeutics that induce KLF4 in the endothelium and monocytes/macrophages are atheroprotective, in part, through the regulation of Ch25h and LXR. Our results demonstrate that KLF4 transactivates Ch25h and LXR in ECs and macrophages in vitro and in vivo. Furthermore, the KLF4-Ch25h/LXR axis is atheroprotective, indicated by the increased atherosclerosis in Ch25h -/-/ApoE -/-mice.
METHODS
See Supplement Methods including Tables I through V in the online-only Data Supplement.
Library Construction and Data Processing
Total RNA was extracted and purified by using the mirVana mRNA (messenger RNA) isolation kit (Thermo Fisher Scientific) according to the manufacturer's instructions. RNA libraries were prepared for sequencing by using standard Illumina protocols. Base calling and quality scoring were performed by an updated implementation of real-time analysis, termed RTA v2, on the NextSeq 500 system. bcl2fastq Conversion Software
Clinical Perspective
What Is New?
• Krüppel-like factor 4, a key anti-inflammatory transcription factor, upregulates cholesterol-25-hydroxylase and liver X receptor in vascular endothelial cells and macrophages.
• This mechanism enhances reverse cholesterol transport from the vascular wall, and mitigates inflammation through suppressing SREBP2 (sterol regulatory-binding protein 2) and NLRP3 (nucleotidebinding oligomerization domain, leucine-rich repeat and pryin domain containing 3) inflammasome in endothelial cells.
• Krüppel-like factor 4-mediated transactivation of cholesterol-25-hydroxylase and liver X receptor also promotes cholesterol efflux and M1 to M2 transition in macrophages.
What Are the Clinical Implications?
• Atherosclerosis is characterized by the accumulation of lipids, including cholesterol, in the vascular wall with a concurrent increase in vascular inflammation.
• The synergism between the anti-inflammatory effects in both endothelial cells and macrophages contributes to the atheroprotective phenotype.
• Because Krüppel-like factor 4 is commonly induced by atheroprotective flow and statins, our results suggest that Krüppel-like factor 4 upregulation of cholesterol-25-hydroxylase and liver X receptor in endothelial cells and macrophages may be a therapeutic target of cardiovascular diseases.
v1.8.4 was used to demultiplex data and convert BCL files to FASTQ file formats. Sequenced reads were trimmed for adaptor sequence and masked for low-complexity or lowquality sequence. Reads were then mapped to the hg19 whole genome for KLF4 overexpression data and mm9 for the Ch25h -/-mouse data using TopHat v2.0.14. 22 Reads per kilobase of exon per megabase of library size were calculated using Cufflinks v2.2.1, 23, 24 which assembles transcripts, estimates their abundances, and tests for differential expression and regulation in RNA-sequencing (RNA-seq) samples.
The mapping statistics of adenovirus (Ad)-KLF4 versus Ad-null RNA-seq data are shown in Figure IA in the onlineonly Data Supplement. Overall, >75% of reads were mapped to the genome. To illustrate the general gene expression pattern of ECs with Ad-KLF4 in comparison with Ad-null, a genome-wide RNA-seq heat map is shown in Figure IB in the online-only Data Supplement. The selected genes with at least 3 reads per kilobase of exon per megabase of library size were used for hierarchical clustering. In addition, the volcano plot in Figure IC in the online-only Data Supplement indicates the thresholds used for analysis.
Gene Expression Network Projection
Gene expression data using fold change from 2 biological repeats of human umbilical vein endothelial cells (HUVECs) infected with Ad-null or Ad-KLF4 were projected to a custom sterol metabolism pathway simplified from the Bloch and Kandustch-Russell pathway. 25 The pathway includes key enzymes and metabolites using Mayachemtools 26 to generate a network GML file to be visualized using Vanted.
27,28

Binding Site Prediction
The potential KLF4 binding sites on selected human and mouse genes were predicted with the use of the weight matrix-based program MATCH 29 to scan the promoter regions of the indicated genes. The promoter regions were defined as -3000 to 500 from the transcriptional start site of the genes. CpG islands were predicted by the WashU EPI Genome Browser. Primers were designed according to ENCODE chromatin immunoprecipitation (ChIP) data.
Intracellular Cholesterol and Cholesterol Efflux Measurements
Intracellular cholesterol level was measured using a cholesterol fluorometric assay kit from Cayman Chemical. In brief, macrophages cultured in 6-well plates were lysed with 0.5% Triton X-100 and centrifuged at 13 000 rpm at 4°C for 30 minutes. Supernatants were then used for the cholesterol measurement. The level of intracellular cholesterol was normalized to the protein concentration of the sample. Cholesterol efflux was measured using the Cholesterol Efflux assay kit from Abcam. In brief, cholesterol was fluorescently labeled and incubated with the isolated peritoneal macrophages (PMs) overnight; high-density lipoprotein was used as the cholesterol acceptor. Fluorescence in the supernatant and cell lysates was measured, and cholesterol efflux was estimated as the percentage ratio of fluorescence intensity in the supernatant to the sum of supernatant and PM lysates.
PM Isolation
Mice were injected with 3% thioglycolate 3 days before euthanization. PMs were isolated from the mouse peritoneal cavity with phosphate-buffered saline. Cells were cultured in Dulbecco's Modified Eagle's medium containing 10% fetal bovine serum and 1% penicillin-streptomycin. /Ch25h +/+ mice were fed a high-fat, highcholesterol diet containing 21% fat and 1.5% cholesterol (D12079B from Research Diet). Twelve weeks after the highcholesterol diet, the aorta was isolated to assess the extent and distribution of atherosclerotic lesions by Oil Red O staining. The lesion area was measured with ImageJ and expressed as a percentage of the total area of aorta. Plasma levels of total cholesterol, high-density lipoprotein cholesterol, LDL cholesterol, and triglycerides were determined by using a kit from Nanjing Jiancheng Bioengineering Institution.
ApoE
Statistical Analysis
All data are expressed as mean±SEM. The Student t test was used for comparisons between 2 groups, or ANOVA for comparisons between multiple groups. If P<0.05 after ANOVA analysis, we then used the Bonferroni post hoc to assess the differences between the 2 indicated groups, with adjusted P<0.05 considered to be statistically significant.
Accession Numbers
The accession number for the transcriptome data of KLF4 overexpression in HUVECs is GSE90982; the accession number for the transcriptome data of PMs isolated from ApoE -/-
Ch25h
-/-mice is GSE90983.
RESULTS
KLF4 Regulates Cholesterol Metabolic Pathways in ECs
Because endothelial homeostasis is manifested by an optimal level of KLF4 in ECs, we performed RNA-seq to investigate the transcriptional profile of ECs with adenovirus-mediated overexpression of KLF4 (Ad-KLF4) in comparison with empty vector (Ad-null). Using gene ontology pathway enrichment tools, ie, Metascape, 30 we analyzed the top 300 upregulated genes to infer the modulated biological processes ( Figure II in Figure 1A) . Following this analysis, we further assessed the KLF4-mediated genes that are associated with lipid regulation. Exhibited in the heat map in Figure 1B and Figure III in the online-only Data Supplement, cholesterol efflux and oxidation genes were upregulated, whereas the cholesterol biosynthesis genes were downregulated. More specifically, LXRα and LXRβ and their targets (eg, ABCA1, ABCG1, ApoE, and MYLIP [myosin regulatory light chain interacting protein]) were upregulated, whereas SREBP2 and its targets (eg, HMG-CoA reductase and squalene epoxidase) were downregulated. In line with the beneficial effects of KLF4, the expression level of genes involved in EC homeostasis (eg, peroxisome proliferatoractivated receptor, eNOS, and IL-10) increased, and that of proinflammatory genes (eg, NLRP3, MCP-1 [monocyte chemoattractant protein]) decreased.
25-HC not only is an agonistic ligand of LXR but also suppresses SREBP2 activation. Thus, the coordinated induction of LXR and suppression of SREBP2 in the RNAseq data suggest that KLF4 might increase the level of 25-HC. 20, 21 Indeed, Ch25h, the enzyme that converts cholesterol to 25-HC, involved in the sterol oxidation KEGG (Kyoto encyclopedia of genes and genomes) pathway (hsa00120), was upregulated by KLF4 ( Figure 1B and 1C) . Figure 1C further highlights the Ch25h-mediated switch from cholesterol biosynthesis suppression to activation of cholesterol efflux genes in a cholesterol regulation network. Thus, we concentrated on the role of Ch25h in KLF4-dependent EC homeostasis.
KLF4 Transactivates Ch25h in ECs
Given the dual role of 25-HC, we postulated that Ch25h is regulated by KLF4 in ECs, which was validated by the increased expression of Ch25h at both the transcriptional and translational levels in ECs overexpressing KLF4 (Figure 2A and 2B). By using lung ECs isolated from mice with endothelial-specific KLF4 overexpression or KLF4 knockout (ie, EC-KLF4-transgenic or EC-KLF4-KO, respectively), we inferred whether KLF4 induces Ch25h in the endothelium in vivo. As expected, the Ch25h mRNA level was significantly lower in ECs from EC-KLF4-KO mice than in ECs from EC-KLF4-transgenic and wild-type controls ( Figure 2C and Figure  IV in the online-only Data Supplement).
Next, we used the bioinformatics tool MATCH to identify 4 putative KLF4 binding sites in the Ch25h promoter region and gene body (ie, -913/902, +607/618, +656/667, and +712/723 base pairs [bp] from the transcriptional start site) based on the KLF4 consensus sequence outlined in Figure 2D . To implement the in silico prediction, we performed ChIP assay to examine whether KLF4 can bind to the Ch25h gene. As shown in Figure 2E , KLF4 overexpression in HUVECs had increased enrichment of KLF4 binding to the Ch25h promoter at the site 1 upstream from the transcriptional start site, whereas the 3 putative sites within the gene body, between +607/618, +656/667, and +712/723 bp, had no significant KLF4 binding. We then created a plasmid construct containing the upstream region of the Ch25h promoter fused to the luciferase reporter (Ch25h-Luc). KLF4 overexpression increased luciferase activity in ECs transfected with Ch25h-Luc in comparison with cells infected with Ad-null ( Figure 2F ). Furthermore, deletion of the region between -913 and -902 bp containing the predicted KLF4 binding site 1 did not induce luciferase activity ( Figure 2F ), indicating that this region is needed for KLF4 binding and transactivation of Ch25h. Because atheroprotective flow is known to increase the expression of KLF4, 1,2 we next investigated whether pulsatile shear stress (PS), which mimics atheroprotective flow in vitro, induces Ch25h in ECs, and if so, whether such induction is KLF4-dependent. As shown in Figure 2G and 2H, the level of KLF4 and Ch25h mRNA and the encoded proteins were all increased by PS, in comparison with atheroprone flow mimicked by oscillatory shear stress. Conversely, KLF4 knockdown using small interfering RNA decreased PSinduced Ch25h ( Figure 2I and 2J). In sum, these results suggest that PS-induced Ch25h is dependent on KLF4 transactivation in ECs.
PS Transcriptionally Induces Ch25h Through Epigenetic Regulation
KLF4 has been suggested to facilitate the recruitment of transcriptional machinery even to genes within compact chromatin. 31 With KLF4 transactivation of Ch25h in the context of atheroprotective flow, we next examined the epigenetic modulations involved in such activation of the Ch25h gene. With use of the WashU EpiGenome Browser, 32 we identified a CpG island located in the Ch25h upstream region between -490 and -989 bp ( Figure 3A ). These publicly available data suggest that the Ch25h promoter/enhancer region resembles a euchromatic state in HUVECs, which is revealed by the enrichment of the histone modifications including H3K27ac, H3K4me1, H3K4me3, and increased binding of RNA polymerase II ( Figure 3A ). To investigate whether PS modulates the euchromatic status of this regulatory region, we used methylation-specific quantitative polymerase chain reaction to detect DNA methylation and histone-ChIP quantitative polymerase chain reaction to identify the levels of histone markers associated with active transcription (ie, H3K4me3 and H3K27ac) in the upstream region of the Ch25h gene. In comparison with oscillatory shear stress, PS significantly decreased DNA methylation, but enriched H3K4me3 and H3K27ac in the upstream region ( Figure 3B A through C, HUVECs were infected with Ad-KLF4 or Ad-null for 48 hours before RNA isolation followed by RNA-sequencing analysis. Data presented are results from 2 biological repeats (Ad-KLF4 divided by Ad-null). A, Gene ontology (GO) enrichment using Metascape of the top 300 upregulated genes plotted as -log(P value). B, Heat map comparison of Ad-null vs Ad-KLF4 using log2-fold changes of the indicated genes (refer to Figure III in the online-only Data Supplement for heat map of scaled z score). C, Network projection of customized sterol metabolism pathway. ABCA1 indicates ATP-binding cassette transporter A1; ABCG1, ATP-binding cassette transporter G1; ACE, angiotensin-converting enzyme; Ad, adenovirus; ApoE, apolipoprotein E; ASC, apoptosis-associated speck-like protein containing a CARD; CASP1, caspase-1; Ch25h, cholesterol-25-hydroxylase; CYP27A1, cytochrome P450 family 27 subfamily A member 1; Cyp51, sterol 14a-demethylase cytochrome P450; CYP7A1, cytochrome P450 family 7 subfamily A member 1; DHCR7, 7-dehydrocholesterol reductase; Dhcr24, 24-dehydrocholesterol reductase; Ebp, emopamil binding protein (sterol isomerase); EC, endothelial cell; EDN1, endothelin 1; eNOS, endothelial nitric oxide synthase; FDFT1, farnesyl-diphosphate farnesyltransferase 1; HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; HUVEC, human umbilical vein endothelial cells; IL-6, interleukin 6; IL-10, interleukin-10; JNK1, c-Jun N-terminal protein kinase 1; JNK2, c-Jun N-terminal protein kinase 2; KLF4, Krüppel-like factor 4; LSS, lanosterol synthase; LXR, liver X receptor; MCP1, monocyte chemotactic protein 1; MEF2A, myocyte-specific enhancer factor 2A; MYLIP, myosin regulatory light chain interacting protein; MVK, mevalonate kinase; NFKB1, nuclear factor kappa B subunit 1; NFKB2, nuclear factor kappa B subunit 2; NLRP3, nucleotide-binding oligomerization domain, leucine-rich repeat and pryin domain containing 3; NOX4, NADPH oxidase 4; Nr1h2, nuclear receptor subfamily 1 group H member 2; Nr1h3, nuclear receptor subfamily 1 group H member 3; PAI1, plasminogen activator inhibitor-1; PMVK, phosphomevalonate kinase; PPARa, peroxisome proliferator-activated receptor alpha; SQLE, squalene epoxidase; Srebf1, sterol regulatory element-binding protein 1; SREBP2, sterol regulatory elementbinding protein 2; THBD, thrombomodulin; and TRAF2, TNF receptor-associated factor 2.
for the facilitation of the Ch25h gene induction. Similar epigenetic modulations were also observed in ECs overexpressing KLF4 (Figure 3E through 3G) .
For in vivo validation of flow-induced Ch25h, we isolated intima, which contains the endothelium, 33, 34 from the aortic arch (AA) and thoracic aorta (TA) of C57BL/6 mice. The flow patterns in AA and TA are atheroprone and atheroprotective, respectively. 35 As shown in Fig- ure 3H, the expression of Ch25h mRNA was increased in the TA in comparison with the AA. DNA methylation was consistently reduced, whereas H3K4me3 and H3K27ac were enriched in the Ch25h promoter in the TA in comparison with the AA (Figure 3I through 3K) . Taken together, these data suggest that epigenetic modulations are highly involved in the atheroprotective flow-induced Ch25h via KLF4. A and B, HUVECs were infected with Ad-KLF4 or Ad-null for 24 hours. Expression levels of KLF4 and Ch25h mRNA and protein were measured by qPCR and Western blot, respectively. C, Lung ECs were isolated from EC-specific KLF4 knockout (EC-KLF4-KO) or EC-specific overexpression of KLF4 (EC-KLF4-Tg) mice (n=3 per group). Levels of KLF4 and Ch25h mRNA were measured by qPCR. D, Depiction of the predicted KLF4 binding sites at -913 to -902 base pairs (bp) (site 1), 607 to 618 bp (site 2), 656 to 667 bp (site 3), and 712 to 723 bp (site 4) in the human Ch25h gene. E, HUVECs infected with Ad-KLF4 or Ad-null were analyzed by ChIP assay with the use of anti-KLF4. KLF4 promoter enrichment was quantified by qPCR. IgG was used as an isotype control. F, Bovine aortic endothelial cells were transfected a luciferase reporter fused with the Ch25h promoter region (Ch25h-Luc) or with a site 1 deletion (Ch25h∆S1-Luc) together with pRSV-β-gal reporter for 6 hours, followed by infection with Ad-KLF4 for an additional 24 hours. Luciferase activity was measured and normalized to that of β-gal. G and H, HUVECs were subjected to OS (1±4 dyne/cm 
KLF4 Transactivates LXR
We next investigated whether the KLF4-Ch25h axis activates LXR. As seen in Figure 4A and 4B, KLF4 overexpression increased the transcription and translation of LXRα. Furthermore, LXRα and its downstream targets, ABCA1 and ABCG1, were found to be reduced in ECs from EC-KLF4-KO in comparison with ECs from EC-KLF4-transgenic and wild-type mice ( Figure 4C and 4D, and Figure IV in the online-only Data Supplement). and Pol II at the promoter of the human Ch25h gene. The epigenetic landscapes shown were from HUVECs without stimulation. B through D, HUVECs were subjected to PS or OS for 12 hours. E through G, HUVECs were infected with Ad-KLF4 or Ad-null for 24 hours. In B and E, DNA methylation status of the Ch25h promoter was measured by methylation-specific (MSP) qPCR. In C, D, F, and G, the binding of H3K4me3 and H3K27ac at the Ch25h promoter was detected using histone-ChIP qPCR. IgG was used as an isotype control. H through K, Intima was collected from the AA or TA regions of C57BL/6 mice (n=9). In H, total mRNA was quantified by qPCR. DNA methylation status is shown in I. The modifications of H3K4me3 and H3K27ac are revealed in J and K. Data presented are mean±SEM from 3 independent experiments. *P<0.05 between the indicated groups. AA indicates aortic arch; Ad, adenovirus; Ch25h, cholesterol-25-hydroxylase; ChIP, chromatin immunoprecipitation; HUVEC, human umbilical vein endothelial cell; IgG, immunoglobulin G; KLF4, Krüppel-like factor 4; mRNA, messenger RNA; OS, oscillatory shear stress; Pol II, polymerase II; PS, pulsatile shear stress; qPCR, quantitative polymerase chain reaction; and TA, thoracic aorta.
To identify whether direct activation of LXR using an agonist could rescue the loss of KLF4, we treated lung ECs isolated from EC-KLF4-KO with T0901317. As shown in Figure VIA in the online-only Data Supplement, T0901317 induced the expression of ABCA1 and ABCG1 to the same level in wild-type and EC-KLF4-KO lung ECs. However, such treatment with LXR agonist reduced the suppression of proinflammatory SREBP2 and NLRP3 in EC-KLF4-KO lung ECs ( Figure VIA in the online-only Data Supplement). These data further suggest that KLF4 is upstream of LXRα; thus, the LXR agonist can restore the anti-inflammatory phenotype seen when KLF4 is knocked out. To investigate the role of endogenous KLF4 in maintaining EC homeostasis in response to lipids, we treated lung ECs from wild-type and EC-KLF4-KO mice with water-soluble cholesterol (ie, cholesterol-methyl-β-cyclodextrin). In wild-type lung ECs, cholesterol treatment induced the expression of Ch25h, LXRα, ABCA1, and ABCG1 ( Figure VIB in the online-only Data Supplement). Cholesterol, as the A and B, HUVECs were infected with Ad-null or Ad-KLF4. Expression levels of LXRα mRNA (A) and protein (B) were measured by qPCR and Western blot, respectively. C and D, The mRNA level of LXRα, ABCA1, and ABCG1 in lung ECs isolated from EC-KLF4-KO or EC-KLF4-Tg mice (n=3 per group) was detected by qPCR. E and F, HUVECs infected with Ad-null or Ad-KLF4 were transfected with control siRNA or Ch25h siRNA. The level of ABCA1, ABCG1, Ch25h, SREBP2, and NLRP3 mRNA was assessed by qPCR. G, Depiction of the predicted KLF4 binding sites at -3643 to 3632 base pairs (bp) (site 1), -419 to -408 bp (site 2), -313 to -302 bp (site3), -219 to -208 bp (site 4), and -133 to -122 bp (site 5) in the human LXRα promoter region. H, HUVECs were infected with Ad-null or Ad-KLF4 followed by ChIP assays using anti-KLF4. IgG was used as an isotype control. I, Bovine aortic endothelial cells were transfected with LXRα-Luciferase together with pRSV-β-gal reporter plasmids followed by infection with Ad-KLF4. Luciferase activity was measured and normalized to that of β-gal. J, HUVECs were transfected with control siRNA or KLF4 siRNA followed by stimulation with PS or kept under static conditions for an additional 24 hours. K, Intima was collected from the AA or TA regions of C57BL/6 mice (n=9). The mRNA expression of LXRα, ABCA1, and ABCG1 was measured by qPCR. Error bars represent mean±SEM from 3 independent experiments. *P<0.05 between the indicated groups. AA indicates aortic arch; ABC, ATP-binding cassette; Ad, adenovirus; Ch25h, cholesterol-25-hydroxylase; ChIP, chromatin immunoprecipitation; Ctrl, control; EC, endothelial cell; HUVEC, human umbilical vein endothelial cell; IgG, immunoglobulin G; KLF4, Krüppel-like factor 4; KO, knockout; LXR, liver X receptor; mRNA, messenger RNA; NLRP3, nucleotide-binding oligomerization domain, leucine-rich repeat and pryin domain containing 3; PS, pulsatile shear stress; qPCR, quantitative polymerase chain reaction; siRNA, small interfering RNA; SREPB2, sterol regulatory element-binding protein 2; TA, thoracic aorta; and Tg, transgenic. Figure VIB in the online-only Data Supplement). Furthermore, when KLF4-KO ECs were treated with cholesterol, NLRP3 was elevated, suggesting that EC homeostasis could not be maintained, and the balance was pushed toward a proinflammatory phenotype (Figure VIB in the online-only Data Supplement). KLF4 overexpression consistently upregulated LXRα target genes (ie, ABCA1 and ABCG1), whereas Ch25h knockdown attenuated the KLF4 induction of ABCA1 and ABCG1 ( Figure 4E ). With respect to EC inflammatory status, KLF4 overexpression suppressed SREBP2 and NLRP3 expression, whereas Ch25h knockdown derepressed these proinflammatory mediators ( Figure 4F ). As a rescue experiment, we found that NLRP3 inflammasome activity, revealed by IL-18 cleavage, was also suppressed when ECs were treated with 25-HC or T0901317 (Figure VIC in the online-only Data Supplement). However, using KLF4 overexpression to attempt to rescue LXR in ECs isolated from Ch25h -/-mice resulted in induction of LXR, ABCA1, and ABCG1, whereas SREBP2 and NLRP3 remained unchanged ( Figure VID . In sum, these data suggest that KLF4-mediated EC homeostasis depends on both Ch25h and LXR.
KLF4 Mitigates Atherosclerosis via Ch25h and LXR
Using MATCH, we predicted the presence of several putative KLF4 binding sites located in the promoter region of the LXRα gene ( Figure 4G ), suggesting that KLF4 may directly transactivate LXRα. It is interesting to note that, according to the WashU EpiGenome Browser, the upstream region of the LXRα gene in unstimulated HUVECs is euchromatic and thus would be accessible for KLF4 binding ( Figure VII in the online-only Data Supplement). Using ChIP assays, we demonstrated that KLF4 overexpression resulted in KLF4 enrichment in the LXRα promoter ( Figure 4H ). Further validation using luciferase reporters determined that KLF4 overexpression increased luciferase activity, which indicated KLF4 transactivation of LXRα ( Figure 4I ). Given that PS transcriptionally upregulates LXRα, 37 we next demonstrated that KLF4 knockdown with small interfering RNA attenuated PS-induced LXRα ( Figure 4J ). For in vivo relevance, we found that LXRα, ABCA1, and ABCG1 expression was augmented in TA in comparison with AA ( Figure 4K ). ECs express both LXRα and LXRβ. 38 It is clear that KLF4 regulated LXRβ in a manner similar to that of LXRα (Figures VII and VII in the online-only Data Supplement). Collectively, data in Figure 4 and Figures VI through VIII in the online-only Data Supplement suggest that PS-induced KLF4 upregulates ABCA1 and ABCG1 in ECs, which is dependent on Ch25h and LXR.
KLF4-Ch25h/LXR Promotes Macrophage Polarization
The atheroprotective role of KLF4 is attributable not only to its effects in ECs but also to its effects in circulating monocytes and resident macrophages in the vessel wall. 6, 7 To examine whether KLF4 regulation of Ch25h and LXR is common in macrophages, we overexpressed KLF4 in a mouse macrophage cell line (ie, RAW264.7 cells). The expressions of Ch25h, LXRα, LXRβ, ABCA1, and ABCG1 were all increased ( Figure 5A ). Furthermore, liquid chromatography-tandem mass spectrometry data suggested that intracellular concentration of 25-HC was increased in cultured THP-1 monocytes overexpressing KLF4 ( Figure 5B ). Similar to ECs, LXR agonist was able to induce the expression of ABCA1 and ABCG1 in PMs isolated from myeloid-specific KLF4-KO (mye-KLF4-KO) mice ( Figure IXA in the online-only Data Supplement). We also examined the role of endogenous KLF4 in macrophages under cholesterol-rich conditions by treating PMs isolated from mye-KLF4-KO or wild-type mice with cholesterol. Results shown in Figure IXB in the onlineonly Data Supplement demonstrated that KLF4 ablation led to reduced cholesterol efflux and enhanced proinflammatory status in PMs. These data suggest that KLF4 may have analogous atheroprotective functions in both ECs and macrophages.
Treating bone marrow-derived macrophages with 25-HC resulted in a temporal suppression of SREBP2 and its downstream targets in cholesterol biosynthesis, whereas it increased Ch25h and LXR targets. 39 Further analysis of these mined data demonstrated that 25-HC also decreased the expression of those involved in NLRP3 inflammasome (ie, NLRP3, ASC [apoptosisassociated speck-like protein containing CARD], IL-1β, and IL-18) and proinflammatory M1 pathways (ie, IL-6, tumor necrosis factor-α, Gro1, and cyclooxygenase-2), whereas it increased anti-inflammatory M2 markers (ie, mannose receptor C-type 1 [Mrc1], arginase-1 [Arg1]) ( Figure 5C ). In light of these analyses, and because KLF4 overexpression in macrophages leads to the M1-to-M2 transition, 5 we investigated the causative effect of Ch25h-25-HC in the KLF4-mediated macrophage polarization. When RAW264.7 cells were treated with 25-HC, we validated that the mRNA expression of proinflammatory genes (eg, NLRP3, IL-1β) and M1 marker genes (ie, cyclooxygenase-2, tumor necrosis factor-α, The mRNA expression profiles were analyzed by microarray as described in Shibata et al. 39 The heat map shown indicates values plotted as relative fold change in comparison with those from untreated controls. D and E, RAW264.7 cells were treated with 25-HC (1 μmol/L) or DMSO for 24 hours (D) or transfected with Ch25h siRNA or control siRNA (E). The mRNA levels of proinflammatory genes (NLRP3, IL-1β), M1 marker genes (COX2, Gro1, TNFα, CCL5, iNOS, and IL-6), and M2 marker genes (PPARγ, MRC, Chil3, Arg1, Retnla, and IL-10) were measured by qPCR. F through I, PMs were isolated from 8-week-old Ch25h -/-mice and their Ch25h +/+ littermates (n=12 per group). The mRNA levels of the indicated genes were quantified by qPCR (F and I) . In G and H, the total cholesterol content and cholesterol efflux were measured. J, PMs isolated from 8-week-old Ch25h -/-mice (n=12) were treated with or without 25-HC (1 μmol/L) for 24 hours. The mRNA levels of indicated genes were measured by qPCR. Error bars represent mean±SEM from 3 independent experiments. *P<0.05 between indicated groups. 25-HC indicates 25-hydroxycholesterol; ABC, ATP-binding cassette; ACC1, acetyl-CoA carboxylase; Ad, adenovirus; Arg1, arginase 1; ASC, apoptosis-associated speck-like protein containing a CARD; BMDM, bone marrow-derived macrophage; CCL5, C-C motif chemokine ligand 5; Ch25h, cholesterol-25-hydroxylase; Chil3, chitinase-like protein 3; COX2, cyclooxygenase 2; Ctrl, control; DHCR7, 7-dehydrocholesterol reductase; DMSO, dimethyl sulfoxide; FASN, fatty acid synthase; FDFT1, farnesyl-diphosphate farnesyltransferase 1; Gro1, chemokine (C-X-C motif) ligand 1; HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; IL, interleukin; KLF4, Krüppel-like factor 4; LC-MS/MS, liquid chromatography-tandem mass spectrometry; LDLR, low-density lipoprotein receptor; LXR, liver X receptor; Mrc, Mannose receptor C-type 1; mRNA, messenger RNA; MVK, mevalonate kinase; MYLIP, myosin regulatory light chain interacting protein; NLRP3, nucleotide-binding oligomerization domain, leucine-rich repeat and pryin domain containing 3; PM, peritoneal macrophage; PMVK, phosphomevalonate kinase; PPARg, peroxisome proliferator-activated receptor gamma; qPCR, quantitative polymerase chain reaction; Retnla, resistin like alpha; siRNA, small interfering RNA; SQLE, squalene epoxidase; SREBP2, sterol regulatory element-binding protein 2; TNFα, tumor necrosis factor alpha; and WT, wild-type. chemokine [C-C motif] ligand 5, inducible nitric oxide synthase , and IL-6) were suppressed, whereas those of the M2 marker genes (ie, peroxisome proliferatoractivated receptor γ, Mrc1, chitinase-like 3 [chil3], Arg1, resistin-like alpha (retnla), and IL-10) were increased ( Figure 5D ). In contrast, Ch25h knockdown in RAW264.7 cells increased the expression of the aforementioned proinflammatory and M1 marker genes, whereas it decreased the mRNA levels of the M2 marker genes in comparison with the control small interfering RNA ( Figure 5E ). Correspondingly, KLF4-mediated M2 markers were inhibited, whereas M1 markers were desuppressed when macrophages were treated with an LXR antagonist ( Figure XA in the online-only Data Supplement). To further examine the role of Ch25h in macrophage polarization in vivo, we isolated PMs from Ch25h -/-mice and their Ch25h +/+ littermates. As seen in Figure 5F through 5H, reduced expression of LXR and LXR targets, increased expression of SREBP and SREBP downstream, a higher total cholesterol content, and decreased cholesterol efflux were found in Ch25h -/-macrophages showed increased levels of inflammatory and M1 markers while suppressing M2 markers (Figure 5I) . As a rescue experiment, Ch25h -/-macrophages coincubated with 25-HC exhibited decreased expression of inflammatory and M1 markers while increasing the expression of M2 markers ( Figure 5J ). Collectively, Figure 5 and Figures IX and X in the online-only Data Supplement demonstrated that KLF4 substantially induced Ch25h and LXR in macrophages, similar to their induction in ECs. Functionally, such induction promoted M2 polarization and regulated cholesterol content, in part, through augmented reverse cholesterol transport.
Ch25h Ablation Increases Atherosclerosis Susceptibility
Because of the involvement of Ch25h-25-HC in functional endothelium and anti-inflammatory phenotype in macrophages, we used Ch25h -/-mice to investigate the comprehensive role of Ch25h in atherosclerosis. We introduced ApoE -/-background into Ch25h -/-mice to promote atherosclerotic lesion development. RNA-seq was performed to confirm the proinflammatory status and M2 to M1 phenotype in PMs isolated from the ApoE -/-/ Ch25h -/-mice. As shown in Figure 6A and Figure XI in the online-only Data Supplement, whereas Ch25h and LXRα were decreased, the proinflammatory chemokine [C-C motif] ligand 5, inducible nitric oxide synthase, and IL-1β were increased in these PMs. , respectively) ( Figure 6B ). In addition, hematoxylin and eosin staining revealed increased cell density that was largely composed of infiltrating macrophages demonstrated by MAC1 staining, and decreased CD31 staining ( Figure 6B ). En face Oil Red O staining revealed that the mean lesion area in the thoracic aorta and that of the aortic arch were also more augmented for ApoE Figure 6C ). Thus, the systemic ablation of Ch25h plays a critical role in accelerated atherosclerosis.
DISCUSSION
The current study encompassing research on both ECs and macrophages provides experimental evidence of the atheroprotective role of KLF4 via the induction of Ch25h and LXR. Initially, RNA-seq data revealed that KLF4, through transactivating Ch25h and LXR, is a novel mediator of cholesterol homeostasis in ECs in addition to its canonical role in nitric oxide biosynthesis, blood vessel, and circulatory system processes. 40, 41 Microarray data from 25-HC-treated bone marrow-derived macrophages ( Figure 5C ) and from PMs isolated from the ApoE -/-/Ch25h -/-mice ( Figure 6A ) indicated that 25-HC, the catalytic product of Ch25h, was essential to preserve the M2 macrophage polarization. Because Ch25h and LXR are critically involved in the cross talk between the immune system and cholesterol metabolism, 42 KLF4 plays an important role in maintaining vascular homeostasis through its regulation of Ch25h and LXR. The implication of this finding at the disease level is that increased atherosclerosis susceptibility is a common phenotype between ApoE -/-/Ch25h -/-( Figure 6 ) and ApoE -/-mice with KLF4 or LXR ablation in the endothelium or macrophages. 16, 19, 43 Given that atherosclerosis is a multifaceted vascular impairment composed of several cell types including ECs and macrophages, 44 the atheroprone phenotype among these mouse lines suggests that the KLF4-Ch25h/LXR axis in ECs and macrophages acts synergistically, which is atheroprotective in vivo.
Serving as a ligand to LXR while inhibiting SREBP2 activation, 25-HC maintains a balance between cholesterol efflux and cholesterol biosynthesis.
11 Cholesterol efflux, regulated by LXR downstream targets such as ABCA1 and ABCG1, is known to be mediated by the innate immune response in macrophages. 45 Furthermore, upregulated SREBP is associated with unresolved innate immunity, leading to inflammasome activation in both ECs and macrophages. 15, 46 Here, we further defined that KLF4 regulates a counterbalance between LXR and SREBP via the regulation of Ch25h-25-HC, although endogenous KLF4 may be supplemental in mitigating LXR responses because target gene expression remains intact even with the loss of KLF4 (Figures VIA and IXA in the online-only Data Supplement). In addition to the beneficial role in regulating LXR and SREBP, 25-HC exerts antiviral effects through inhibiting viral particle uptake 11 and activates integrated stress response genes to reprogram transcription and translation. 38 However, the anti-inflammatory role of 25-HC remains somewhat controversial because others have indicated that the oxysterol promotes macrophage foam cell formation and is increased in atherosclerotic lesions. 47 Such contradiction may be attributable, in part, to the differences in experimental conditions and requires further investigation. +/+ littermates (n=10 per group). Graphs on the right represent quantification of the lesion area in thoracic aorta (TA) vs aortic arch (AA), and the total lesion area, as well, summed from that of AA (ie, aortic root, ascending aorta, and descending thoracic aorta to the fourth thoracic vertebra), TA (ie, descending aorta from the fourth thoracic vertebra to the renal arteries), and abdominal aorta (ie, below the renal arteries). Error bars represent mean±SEM from 3 independent experiments. *P<0.05 between the indicated groups. ApoE indicates apolipoprotein E; Arg1, arginase 1; CCL5, C-C motif chemokine ligand 5; Ch25h, cholesterol-25-hydroxylase; COX2, cyclooxygenase 2; IL, interleukin; iNOS, inducible nitric oxide synthase; LXRα, liver X receptor alpha; MAC1, macrophage-1 antigen; PM, peritoneal macrophage; and Retnla, resistin-like alpha.
Endothelial and macrophage homeostasis relies on an optimal level of KLF4, which can be induced by both physiological and pharmacological stimuli such as shear stress and statins. 47 At the tissue level, KLF4 overexpression in the endothelium is atheroprotective. 6 Because of the sequence homology between KLF4 and KLF2, and because both are well known in atheroprotection, 48, 49 we also examined the role of KLF2 in Ch25h expression. As shown in Figure XII in the online-only Data Supplement, KLF2 increased Ch25h mRNA and protein expression. In light of statin-induced KLF2 and KLF4 in ECs, 48 we also found that statin treatment of ECs increased Ch25h in a KLF4-dependent manner ( Figure V in the online-only Data Supplement). If statin can activate KLF4 in the endothelium in vivo, the consequent induction of Ch25h and LXR would be one of the pleotropic effects of statin therapy. KLF4 also mediates macrophage polarization, because KLF4 is drastically induced in M2 macrophages but significantly reduced in M1 macrophages. 5 Phenotypically, mice with myeloid KLF4 deficiency are characterized by increased bactericidal activity and delayed wound healing, signifying M1 polarization. 5 Collectively, our data support that Ch25h-25-HC plays a major role in the vascular beneficial effects caused by physiological and pharmacological stimuli (eg, PS and statins) that activate KLF4.
Regarding stimuli that downregulate KLF4 in the vasculature, we and others have previously shown that oxidative and inflammatory burdens, exemplified by oxidized LDL, angiotensin II, and hydrogen peroxide, activate the SREBP2-microRNA-92a axis, which in turn suppresses KLF4 in ECs. 50 Thus, under atherogenic conditions, the KLF4 level is likely to be reduced in both the endothelium and macrophages via SREBP2-microRNA92a. Noticeably, KLF4 overexpression not only increased the level of Ch25h and LXR but also reduced SREBP2 and microRNA-33 ( Figure XIII in the online-only Data Supplement). Given microRNA-33 targets ABCA1 and ABCG1, 51 aberrant KLF4 expression may feed forward to further downregulate reverse cholesterol transport. Furthermore, single and double ablation of mouse abca1 and abcg1, specifically in the endothelium, are proatherogenic, not only through the reduction in reverse cholesterol transport but also through the perturbation of eNOS. 52 In conjunction with the current study, the suggested mechanisms constitute a regulatory network linking endothelial dysfunction and macrophage polarization, which aggravates atherosclerosis ( Figure 7) . KLF4 has been suggested to be a "pioneer transcription factor" along with OCT4 (octamer-binding transcription factor 4), c-MYC (V-Myc avian myelocytomatosis viral oncogene homolog), and SOX2 (sex determining region Y-box 2). 31 Pioneer transcription factors are able to directly bind to DNA and modify nucleosome complexes, allowing the chromatin structure to relax. 53 We found that KLF4 transactivation of Ch25h, LXRα, and LXRβ involves direct cis-element binding measured through ChIP assays ( Figures 2E and 4H and Figure VIIID in the online-only Data Supplement). Furthermore, KLF4 can function as a transcriptional repressor of SREBP2. 54 Therefore, we performed ChIP assays for key cholesterol efflux/oxidation and cholesterol biosynthesis genes to define a range of KLF4 direct interactions. Further analysis demonstrated that KLF4 can directly bind to ABCA1, ABCG1, and ApoE to promote expression while also binding to SREBP2 and mevalonate kinase to suppress transcription ( Figure XIV in the online-only Data Supplement). Thus, beneficial stimuli that enhance KLF4 expression, such as atheroprotective flow and statins, would increase KLF4 interaction with the cognate DNA-binding sequences. Further chromatin relaxation is likely through the transdependent modifications of H3K27ac and H3K4me3, as shown in Figure 3 . In addition, both atheroprotective flow and Atheroprotective factors, such as pulsatile shear stress (PS) and statins, induce KLF4 in ECs and macrophages. KLF4 then transactivates Ch25h and LXR, thereby promoting the suppression of SREBP2 and NLRP3 inflammasome in ECs, and promoting cholesterol efflux and M1 to M2 transition in macrophages, as well. The synergism between the antiinflammatory effects in both ECs and macrophages contributes to the atheroprotective phenotype. ABC indicates ATP-binding cassette; Ch25h, cholesterol-25-hydroxylase; EC, endothelial cell; 25-HC, 25-hydroxycholesterol; KLF4, Krüppel-like factor 4; LXR, liver X receptor; NLRP3, nucleotide-binding oligomerization domain, leucine-rich repeat and pryin domain containing 3; and SREPB2, sterol regulatory element-binding protein 2.
KLF4 overexpression reduced DNA methylation in the promoter region of Ch25h. However, promoter methylation of several atheroprotective genes was increased by atheroprone flow, resulting from increased expression of DNA methyltransferase 1 and DNA methyltransferase 3a. 55, 56 KLF4 is able to directly bind to methylated DNA. The mechanism by which remains elusive but has been suggested to be required for cellular reprogramming and stem cell differentiation. 57, 58 As a pioneering transcription factor, whether KLF4 regulates the epigenetic landscape of an array of genes crucial for EC function at the genome-wide scale warrants further study. In summary, this study identifies that KLF4 is a mediator for both Ch25h and LXR in ECs and macrophages. Because atherogenesis includes dysfunctional endothelium and M1 polarized macrophages with attendant decrease of KLF4, we suggest that the congruent KLF4-Ch25h/LXR axis in both cell types is antiatherogenic.
